Literature DB >> 25891445

Adenosine A2 a receptor stimulation prevents proteinuria in diabetic rats by promoting an anti-inflammatory phenotype without affecting oxidative stress.

P Persson1, M Friederich-Persson1, A Fasching1, P Hansell1, R Inagi2, F Palm1,3,4.   

Abstract

AIM: Diabetic patients are at increased risk for kidney disease. There is presently no clinical treatment available that effectively protects kidney function in diabetics. This study investigates whether chronic stimulation of the adenosine A2a receptor (A2a AR) protects kidney function in insulinopenic diabetic rats.
METHODS: Streptozotocin-induced diabetic rats and corresponding controls were chronically treated with the adenosine A2a AR agonist CGS21680 throughout the four-week diabetes duration. Kidney function was thereafter investigated, and urine and plasma samples were collected for analysis of protein, oxidative stress and inflammatory markers.
RESULTS: Glomerular filtration rate, renal blood flow, filtration fraction and diabetes-induced kidney hypoxia were all unaffected by chronic A2a AR stimulation. Furthermore, diabetic rats had increased oxidative stress, which was further increased by chronic A2a AR stimulation. However, the 10-fold increased urinary protein excretion observed in the diabetic rats was completely prevented by chronic A2a AR stimulation. These beneficial effects were accompanied by reduced levels of the pro-inflammatory TNF-α and increased levels of the anti-inflammatory IL-10 as well as decreased infiltration of macrophages, glomerular damage and basement membrane thickness.
CONCLUSION: Chronic A2a AR stimulation prevents proteinuria and glomerular damage in experimental diabetes via an anti-inflammatory mechanism independent of oxidative stress and kidney hypoxia.
© 2015 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CGS21680; diabetes mellitus; diabetic nephropathy; kidney; macrophages; tumour necrosis factor-alpha

Mesh:

Substances:

Year:  2015        PMID: 25891445     DOI: 10.1111/apha.12511

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  7 in total

1.  Endothelin type A receptor inhibition normalises intrarenal hypoxia in rats used as a model of type 1 diabetes by improving oxygen delivery.

Authors:  Stephanie Franzén; Fredrik Palm
Journal:  Diabetologia       Date:  2015-07-15       Impact factor: 10.122

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 3.  Alteration of purinergic signaling in diabetes: Focus on vascular function.

Authors:  Rui Zhou; Xitong Dang; Randy S Sprague; S Jamal Mustafa; Zhichao Zhou
Journal:  J Mol Cell Cardiol       Date:  2020-02-11       Impact factor: 5.000

Review 4.  Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.

Authors:  Stacy A Johnson; Robert F Spurney
Journal:  Am J Physiol Renal Physiol       Date:  2015-09-02

5.  Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration.

Authors:  Patrycja Koszałka; Monika Gołuńska; Aleksandra Urban; Grzegorz Stasiłojć; Marcin Stanisławowski; Marceli Majewski; Andrzej C Składanowski; Jacek Bigda
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

Review 6.  Hyperhomocysteinemia and Cardiovascular Disease: Is the Adenosinergic System the Missing Link?

Authors:  Franck Paganelli; Giovanna Mottola; Julien Fromonot; Marion Marlinge; Pierre Deharo; Régis Guieu; Jean Ruf
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

7.  SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease.

Authors:  Yong-Ping Lu; Ze-Yu Zhang; Hong-Wei Wu; Li-Jing Fang; Bo Hu; Chun Tang; Yi-Qing Zhang; Lianghong Yin; Dong-E Tang; Zhi-Hua Zheng; Ting Zhu; Yong Dai
Journal:  J Transl Med       Date:  2022-09-14       Impact factor: 8.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.